MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
188.57
-3.38
-1.76%
Opening 09:48 07/15 EDT
OPEN
191.21
PREV CLOSE
191.95
HIGH
191.21
LOW
186.03
VOLUME
150.25K
TURNOVER
--
52 WEEK HIGH
219.72
52 WEEK LOW
121.05
MARKET CAP
27.84B
P/E (TTM)
20.24
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Biogen (BIIB)
TipRanks · 11h ago
Tau In The Clinic, Again
Seeking Alpha · 12h ago
Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s Data - Has The Bull Case Changed?
Simply Wall St · 13h ago
Biogen: LEQEMBI Real-World LEADER Study Shows Majority Of Early Alzheimer's Patients Remain Stable
NASDAQ · 15h ago
Biogen: CELIA Phase 2 Data Underpin Continued Confidence in Diranersen; Buy Rating and $256 Price Target Reiterated
TipRanks · 23h ago
Analysts Are Bullish on Top Healthcare Stocks: Atea Pharmaceuticals (AVIR), Biogen (BIIB)
TipRanks · 1d ago
Biogen Inc. Stock Slips 8.2%, Underperforms Peers
Dow Jones · 1d ago
Biogen's Alzheimer's Drug Leaves Questions Unanswered, and That's a Problem
Barron‘s · 1d ago
More
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.